pentadecapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-11. Numbers and descriptions here follow the published literature rather than marketing material.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
== O == Okazaki fragment – olfaction – oncogene – operator (biology) – operon – organ – organelle – organism – origin of life – Oscar Hertwig – osmosis – osmoregulation – Oswald Avery – outbreak – outline of biochemical techniques – ovalbumine – ovary – ovum – oxidation – oxidative decarboxylation – oxidative phosphorylation
== External links == Clinical trial number NCT03669588 for "An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness (ADAPT)" at ClinicalTrials.gov
=== Structural domain === A structural domain is an element of the protein's overall structure that is self-stabilizing and often folds independently of the rest of the protein chain. Many domains are not unique to the protein products of one gene or one gene family but instead appear in a variety of proteins. Domains often are named and singled out because they figure prominently in the biological function of the protein they belong to; for example, the "calcium-binding domain of calmodulin". Because they are independently stable, domains can be "swapped" by genetic engineering between one protein and another to make chimera proteins. A conservative combination of several domains that occur in different proteins, such as protein tyrosine phosphatase domain and C2 domain pair, was called "a superdomain" that may evolve as a single unit.
=== Arrays === Lectin and antibody arrays provide high-throughput screening of many samples containing glycans. This method uses either naturally occurring lectins or artificial monoclonal antibodies, where both are immobilized on a certain chip and incubated with a fluorescent glycoprotein sample. Glycan arrays, like that offered by the Consortium for Functional Glycomics and Z Biotech LLC, contain carbohydrate compounds that can be screened with lectins or antibodies to define carbohydrate specificity and identify ligands.
== Reaction mechanism == The nucleophilic attack on the carbonyl group proceeds via the Bürgi-Dunitz trajectory. The angle between the line of nucleophilic attack and the C-O bond is greater than 90˚ due to a better orbital overlap between the HOMO of the nucleophile and the π* LUMO of the C-O double bond.
Sources: en.wikipedia.org
{\displaystyle \left(\mathbf {w} _{i},{\frac {\partial \mathbf {u} _{j}}{\partial t}}\right)=-{\bigl (}\mathbf {w} _{i},\left(\mathbf {u} \cdot \nabla \right)\mathbf {u} _{j}{\bigr )}-\nu \left(\nabla \mathbf {w} _{i}:\nabla \mathbf {u} _{j}\right)+\left(\mathbf {w} _{i},\mathbf {f} ^{S}\right).}
Afghanistan: The Foreign Ministry stipulated that the Assad regime was the "cause of war and instability" and congratulated Tahrir al-Sham. Canada: Prime Minister Justin Trudeau said that the fall of the Assad dictatorship "ends decades of brutal oppression" and said that Canada is monitoring the transition closely. China: The Foreign Ministry stated that it "is closely following the development of the situation in Syria and hopes that Syria returns to stability as soon as possible" and urged all parties to ensure the safety of Chinese citizens in Syria. European Union: EU foreign policy chief Kaja Kallas called the end of Assad's rule a "positive and long-awaited development" and stated she was in close contact with regional ministers. She emphasized that rebuilding Syria would be "long and complicated". France: President Emmanuel Macron commented on social media: "The barbaric state has fallen. At last. I pay tribute to the Syrian people, to their courage, to their patience." He added that France would remain committed to security in the Middle East. Germany: Foreign Minister Annalena Baerbock described the end of the Assad regime as "a big relief for millions of people in Syria" while warning that "the country must not fall into the hands of other radicals". Indonesia: The Ministry of Foreign Affairs reported that the Embassy of Indonesia in Damascus attacked by stray bullets from the Syrian Opposition Forces and causing minor damages to the building on 9 December 2024. No casualties and injured reported from the attack.
The cords of Billroth (also known as splenic cords or red pulp cords) are found in the red pulp of the spleen between the sinusoids, consisting of fibrils and connective tissue cells with a large population of monocytes and macrophages. These cords contain half of the human body's monocytes as a reserve so that, after tissue injury, these monocytes can move in and aid locally sourced monocytes in wound healing. Erythrocytes pass through the cords of Billroth before entering the sinusoids. The passage into the sinusoids may be seen as a bottleneck, where erythrocytes need to be flexible in order to pass through. In disorders of erythrocyte shape and/or flexibility, such as hereditary spherocytosis, erythrocytes fail to pass through and get phagocytosed, causing extravascular hemolysis.
The enzyme is believed to act on the so-called "quinonoid" form of the starting dihydrobiopterin. This is in contrast to the enzyme dihydrofolate reductase, which normally acts on dihydrofolic acid but can also reduce the isomer, L-erythro-7,8-dihydrobiopterin.
Sources: en.wikipedia.org
== Phylogenetics of cytochrome c == Cytochrome c is a highly conserved protein across the spectrum of eukaryotic species, found in plants, animals, fungi, and many unicellular organisms. This, along with its small size (molecular weight about 12,000 daltons), makes it useful in studies of cladistics. Cytochrome c has been studied for the glimpse it gives into evolutionary biology. Cytochrome c has a primary structure consisting of a chain of about 100 amino acids. Many higher-order organisms possess a chain of 104 amino acids. The sequence of cytochrome c in humans is identical to that of chimpanzees (our closest relatives), but differs from that of horses. Cytochrome c has an amino acid sequence that is highly conserved in eukaryotes, varying by only a few residues. In more than thirty species tested in one study, 34 of the 104 amino acids were conserved (identical at their characteristic position). For example, human cytochrome oxidase reacted with wheat cytochrome c, in vitro; which held true for all pairs of species tested. In addition, the redox potential of +0.25 volts is the same in all cytochrome c molecules studied.
== Further reading == "Bernie Sanders Explains... Why Americans Are Furious at the Democrats: The Nation Interview [by John Nichols]", The Nation, vol. 321, no. 4 (November 2025), pp. 30–34. "[T]he [Democratic] party is saying, '[W]e can't support [Zohran Mamdani, running for New York City mayor] because he is saying what 75 percent of Democrats say about Israel: No more money for Netanyahu.' [p. 32.] [T]he money people decide who the candidates are... [p. 33.] A few years ago ... a poll [showed that] [a]lmost 60 percent of the people said [they] were better off 50 years ago. [p. 34.]" Chiasson, Dan (2026). Bernie for Burlington: The Rise of the People's Politician. New York: Knopf. ISBN 978-0-59331-749-5. Rall, Ted (2016). Bernie. New York: Hollowbrook Publishing. ISBN 978-1-60980-698-9. Rice, Tom W. (1985). "Who Votes for a Socialist Mayor?: The Case of Burlington, Vermont". Polity. 17 (4): 795–806. doi:10.2307/3234575. ISSN 0032-3497. JSTOR 3234575. OCLC 5546248357. S2CID 153889856. Rosenfeld, Steven (1992). Making History in Vermont: The Election of a Socialist to Congress. Wakefield, NH: Hollowbrook Publishing. ISBN 978-0-89341-698-0. LCCN 91034055. OCLC 24468446. OL 1553980M. Soifer, Steven (1991). The Socialist Mayor: Bernard Sanders in Burlington, Vermont. Westport, CN: Praeger. ISBN 978-0-89789-219-3. LCCN 90048954. OCLC 22491683. OL 1887682M.
== History == The earliest fully documented case of aortic dissection is attributed to Frank Nicholls in his autopsy report of King George II of Great Britain, who had been found dead on 25 October 1760; the report describes a dissection of the aortic arch and into the pericardium. The term "aortic dissection" was introduced by the French physician J. P. Maunoir in 1802, and René Laennec labeled the condition "dissecting aneurysm". London cardiologist Thomas Bevill Peacock contributed to the understanding of the condition by publishing two series of the cases described in the literature so far: 19 cases in an 1843 review, and 80 in 1863. The characteristic symptom of tearing pain in the chest was recognized in 1855 when a case was diagnosed in life. Surgery for aortic dissection was first introduced and developed by Michael E. DeBakey, Denton Cooley, and Oscar Creech, cardiac surgeons associated with the Baylor College of Medicine, Houston, Texas, in 1954. DeBakey developed aortic dissection himself at age 97 in 2005, and underwent surgery in 2006. Endovascular treatment of aortic dissection was developed in the 1990s.
A small N-terminal domain (160 amino-acid residues) A large C-terminal domain (240 amino-acid residues) Each noncovalently-associated monomer subunit consists of both domains. The subunits interact with each other through about 20 hydrogen bonds and four ion pairs, providing stability to the dimer. The two domains in each monomer subunit are more loosely connected, with only six hydrogen bonds and one ion pair between them, and no intra- or intermolecular disulfide bonds. Looking more closely at the two domains, the following structures were described in 1988:
In 1974, Steely Dan guitarist Jeff "Skunk" Baxter learned that his band was retiring from the road and that Donald Fagen and Walter Becker intended to work almost exclusively with session players in the future. In need of a steady gig, he joined the Doobie Brothers as third lead guitarist in the middle of their tour. He had previously worked with the band both live and in the studio, adding pedal steel guitar to both The Captain and Me ("South City Midnight Lady") and What Were Once Vices Are Now Habits ("Black Water", "Tell Me What You Want") and was already playing with the band as a special guest during that year's tour. What Were Once Vices Are Now Habits included the band's first No. 1 single, Simmons' signature tune "Black Water". It topped the charts in March 1975 and eventually propelled the album to multi-platinum status. Johnston's lyrical "Another Park, Another Sunday" (as a single, it featured "Black Water" as the B-side) and his horn-driven funk song "Eyes of Silver" also charted the year before at numbers 32 & 52, respectively. During this period and for several subsequent tours, the Doobies were often supported on stage by Stax Records mainstays the Memphis Horns. Live recordings with the horn section have aired on radio on the King Biscuit Flower Hour, but none have been officially released. The Memphis Horns also appeared as session players on multiple Doobies albums. By the end of 1974, Johnston's health was suffering from the rigors of the road.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.